Baby KJ researchers publish FDA interactions as agency eyes new pathwaynews2025-10-31T19:14:34+00:00October 31st, 2025|Endpoints News|
FDA commissioner says more ‘deregulatory’ action coming soonnews2025-10-31T17:33:28+00:00October 31st, 2025|Endpoints News|
HHS approves 340B rebate model plans for Merck, Bristol Myers and othersnews2025-10-30T19:47:44+00:00October 30th, 2025|Endpoints News|
FDA puts two Intellia CRISPR trials on hold following liver toxicity casenews2025-10-30T13:45:08+00:00October 30th, 2025|Endpoints News|
FDA to reduce regulatory red tape for biosimilarsnews2025-10-29T16:43:48+00:00October 29th, 2025|Endpoints News|
FDA clears at-home use for Delix’s next neuroplastogen studynews2025-10-28T19:22:46+00:00October 28th, 2025|Endpoints News|
FDA’s biosimilars director says agency seeks to ‘streamline’ developmentnews2025-10-28T18:41:12+00:00October 28th, 2025|Endpoints News|
FDA names Mary Thanh Hai as permanent director of Office of New Drugsnews2025-10-27T15:48:22+00:00October 27th, 2025|Endpoints News|
FDA names Mary Thanh Hai as permanent director of Office of New Drugsnews2025-10-27T15:48:22+00:00October 27th, 2025|Endpoints News|
FDA approves Bayer’s hot flash treatmentnews2025-10-24T20:16:36+00:00October 24th, 2025|Endpoints News|
